Xiya Reagent: deal adds a fourth clinical CAR-T candidate to Jun

The deal adds a fourth clinical CAR-T candidate to Juno's portfolio of potential therapies. Leading the way is JCAR015, an ALL treatment whose stellar Phase I results led the FDA to grant a breakthrough therapy designation last month, promising an expedited regulatory review. Behind that is JCAR017, in development for ALL and NHL, followed by JCAR014, which is undergoing early studies on various B cell malignancies.

Meanwhile, Juno is queued up to make a splash on Wall Street after filing for a $150 million IPO last month. The biotech has turned heads since its launch last year, raising more than $300 million in venture cash and reporting excellent clinical results for its cadre of cancer treatments, including complete remission rates above 90% in ALL.

Now it's locked in competition with Novartis ($NVS), which is developing a similar--and similarly promising--CAR-T therapy alongside the University of Pennsylvania. And the technology's promise has brought a host of contenders to the table, including oncology heavyweight Celgene ($CELG), which reached out to gene therapy pioneer bluebird bio ($BLUE) to get to work in the space, and Santa Monica, CA's Kite Pharma ($KITE), which grossed more than $140 million in a June IPO on the strength of its approach to T cell modification. Late-comer Johnson & Johnson ($JNJ) has shouldered its way into CAR-T with a $292 million deal signed last month.· 以上资料由西亚试剂：http://www.xiyashiji.com/ 提供此产品的详细信息如密度,含量,分子式,分子量等均可在西亚官网查询